News and Events

Hatchtech headlice treatment to go to Phase II trial after US FDA green light to IND

21/01/2008 | Press Releases

The US Food and Drug Administration (FDA) has accepted Hatchtech’s Investigational New Drug (IND) application allowing immediate commencement of Phase II clinical trials of the new ovicidal head lice treatment DeOvo™. These are multi-centre international trials and come after Hatchtech successfully completed DeOvo™ Phase I studies in Australia in 2007.

Download PDF